Bone loss associated with use of antiepileptic drugs

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 561-571

  Nakken, Karl O ^a   Taubøll, Erik ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

adverse effects; antiepileptic drugs; bone health; epilepsy; osteoporosis

Indexed keywords

ACETAZOLAMIDE; ANTACID AGENT; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BONE DENSITY CONSERVATION AGENT; CARBAMAZEPINE; CLONAZEPAM; CYCLOSPORIN A; CYTOSTATIC AGENT; ETHOSUXIMIDE; GLUCOCORTICOID; GONADORELIN; HEPARIN; HISTONE DEACETYLASE INHIBITOR; LAMOTRIGINE; LITHIUM; MEDROXYPROGESTERONE ACETATE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ALCOHOL CONSUMPTION; BONE DENSITY; BONE METABOLISM; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPOCALCEMIA; IMMOBILIZATION; LONG TERM CARE; METABOLIC ACIDOSIS; OSTEOPENIA; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SMOKING; SUN EXPOSURE; VERTEBRA FRACTURE; ANIMAL; BONE; BONE DEVELOPMENT; CHEMICALLY INDUCED; DRUG EFFECTS; FRACTURE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTICONVULSANTS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; EPILEPSY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 77953735011     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003636475     Document Type: Review

References (116)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16(2):165-170
2. Svendsen T, Lossius M, Nakken KO. Age-specific prevalence of epilepsy in Oppland County, Norway. Acta Neurol Scand 2007;116(5):307-311
3. Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63:S24-9
4. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004;5:S36-40
5. Pedersen KK, Christiansen C, Ahlgren P, et al. Incidence of fractures of the vertebral spine in epileptic patients. Acta Neurol Scand 1976;54(2):200-203
6. Sheth RD. Bone health in pediatric epilepsy. Epilepsy Behav 2004;5:S30-5
7. Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004;5:S3-15
8. Valsamis HA, Arora SK, Labban B, et al. Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 2006;3:36
9. Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 2008;83:305-328
10. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5:S41-7
11. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004;5:S24-9
12. Sheth RD. Bone health in epilepsy. Lancet Neurol 2004;3(9):516
13. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt) 2006;15(6):709-719
14. Lofthus CM, Osnes EK, Falch JA, et al. Epidemiology of hip fractures in Oslo, Norway. Bone 2001;29(5):413-418
15. Elliott JO. Possible methods for the prevention of bone loss in persons with epilepsy. Expert Rev Neurother 2009;9(6):797-812
16. Tucker KL. Osteoporosis prevention and nutrition. Curr Osteoporos Rep 2009;7(4):111-117
17. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008;17:181-186
18. Kok C, Sambrook PN. Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin Rheumatol 2009;23(6):769-779
19. Valmadrid C, Voorhees C, Litt B, et al. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374
20. Epilepsy Action (UK). Anti-epileptic drugs and the risk of osteoporosis and osteomalcia: how much information do patients taking anti-epileptic drugs feel they receive about side effects of this medication? British Epilepsy Association, Leeds, UK; 2003
21. Landmark CJ. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22(1):27-47
22. Bergqvist AGC, Schall JI, Stallings VA, et al. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogen diet. Am J Clin Nutr 2008;88:1678-1684
23. Elliott ME, Binkley N. Evaluation and measurement of bone mass. Epilepsy Behav 2004;5:S16-23
24. WHO Study Group. Assessment of fracture risk and its application to screening of postmenopausal osteoporosis. Genève: WHO Technical Report Series, No.843: 1994
25. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodelling: current status and future directions. Osteoporos Int 2000;11:467-480
26. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS drugs 2001;15(8):633-642
27. Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66(9):1318-1324
28. Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009;50(9):2140-2146
29. Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-2057
30. Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. BMJ 1970;4(5727):73-76
31. Vestergaard P. Epilepsy, osteoporosis and fracture risk - meta-analysis. Acta Neurol Scand 2005;112(5):277-286
32. Persson HB, Alberts KA, Farahmand BY, et al. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-772
33. Koppel BS, Harden CL, Nikolov BG, et al. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005;111(4):225-228
34. Vanheer P, van Rhijn J, Boel M, et al. Supracondylar femur fracture complicating epileptic insult: a specific and under diagnosed complication? Acta Neurol Belg 2008;108(1):17-20
35. Pappademos PC, Hamilton WG. Bilateral displaced femoral neck fractures after myoclonic seizures treated with bilateral total hip arthroplastics. Am J Orthop 2009;38(2):88-89
36. Wirrell EC. Epilepsy-related injuries. Epilepsia 2006;47(Suppl 1):79-86
37. Nakken KO, Lossius R. Seizure-related injuries in multihandicapped patients with therapy-resistant epilepsy. Epilepsia 1993;34:836-840
38. Dubost JJ, Vernay D, Soubrier M, et al. Vertebral compression in epilepsy. Analysis of 8 cases. Rev Med Intern 1993;14(5):294-296
39. McCullen GM, Brown CC. Seizure-induced thoracic burst fractures. A case report. Spine 1994;19(1):77-79
40. Youssef JA, McCullen GM, Brown CC. Seizure-induced lumbar burst fracture. Spine 1995;20(11):1301-1303
41. Gnanalingham K, Maconovic M, Joshi S, et al. Non-traumatic compression fractures of the thoracic spine following a seizure - treatment by percutaneous kyphoplasty. Minim Invasiv Neurosurg 2004;47(4):256-257
42. Beerhorst K, Huvers FC, Renier WO. Severe early onset osteopenia and osteoporosis caused by antiepileptic drugs. Neth J Med 2005;63(6):222-226
43. Aboukasm AG, Smith BJ. Nocturnal vertebral compression fracture. A presenting feature of unrecognized epileptic seizures. Arch Fam Med 1997;6(2):185-187
44. Roohi F, Fox A. Burst fracture of the first lumbar vertebra and conus-cauda syndrome complicating a single convulsive seizure: a challenge of diagnosis in the Emergency Department. J Emerg Med 2006;31(4):381-385
45. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8(6):339-342
46. Sheth RD, Binkley N, Hermann BP. Progressive bone loss in epilepsy. Neurology 2008;70(3):170-176
47. Phabphal K, Geater A, Leelawattana R, et al. Prevalence and risk factors of low bone mineral density and 25-hydroxyvitamin D status in young healthy epileptic adult patients in a tropical Asian country taking antiepileptic drugs. Bone 2009;45(2):232-237
48. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9(5):631-637
49. Pack AL, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-257
50. Verotti A, Greco G, Morese G, et al. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-388
51. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449
52. Ecevit C, Aydogan A, Kavakli T, et al. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004;31(4):279-282
53. Boluk A, Guzelipek M, Savli H, et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50(1):93-97
54. Mintzer S, Boppana P, Toguri J, et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47(3):510-515
55. Cetinkaya Y, Kurtulmus YS, Tutkavul K, et al. The effect of oxcarbazepine on bone metabolism. Acta Neurol Scand 2009;120:170-175
56. Guo C-Y, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42:1141-1147
57. Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007;10(2):291-295
58. Leung A, Ramsay E. Effect of topiramate on bone resorption in adults [abstract]. Am Epilepsy Soc 2006;2:150
59. Nissen-Meyer LSH, Svalheim S, Taubøll E, et al. Levetiracetam, phenytoin and valproate act differently on rat bone mass, structure and metabolism. Epilepsia 2007;48(10):1850-1860
60. Hunter J, Maxwell JD, Stewart DA, et al. Altered calcium metabolism in epileptic children on anticonvulsants. BMJ 1971;4(5781):202-204
61. Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975;41(06):1130-1135
62. Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence og different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986;59(230):569-577
63. Hoikka V, Savolainen K, Esko M, et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981;64:122-131
64. Bogliun G, Beghi E, Crespi V, et al. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986;74:284-288
65. El-Hajj Fuleihan G, Dib L, Yamout B, et al. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008;43(1):149-155
66. Lyngstad-Brechan MA, Taubøll E, Nakken KO, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 2008;68:759-766
67. Farhat G, Yamout B, Mihati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353
68. Hahn TJ, Hendin BA, Scharp CR, et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-904
69. Stamp TC, Round JM, Rowe DJ, et al. Plasma levels and therapeutic effect of 25-hydroxycholecalceferol in epileptic patients taking anticonvulsant drugs. BMJ 1972;4(5831):9-12
70. Tjellesen L, Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand 1982;66(3):335-341 (Pubitemid 12061608)
71. Gaitatzis A, Carroll K, Majeed A, et al. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45(12):1613-1622
72. Sheth RD, Gidal BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav 2006;9(4):601-605
73. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786
74. Annegers JF, Melton LJ, Sun CA, et al. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989;30:348-355
75. Cummings S, Nevitt M, Browner W, et al. Risk factors for hip fractures in white women. N Engl J Med 1995;332:767-773
76. Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005;46(2):304-310
77. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45(11):1330-1337 (Pubitemid 39470036)
78. Tsiropoulos I, Andersen M, Nymark T, et al. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008;49(12):2092-2099
79. Vestergaard P. Epilepsy, osteporosis and fracture risk - meta-analysis. Acta Neurol Scand 2005;112(5):277-286
80. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262
81. Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrin Diab 2000;108:37-43
82. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007;18:129-142
83. Koch HV, Kraft D, von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972;13:829-841
84. Corradino RA. Diphenylhydantoin: direct inhibition of the vitamin D3-mediated calcium absorptive mechanism in organ-cultured duodenum. Biochem Pharmacol 1976;25:863-864
85. Bell RD, Pak CY, Zerwekh J, et al. Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol 1979;5:374-378
86. Hahn TJ, Hendin BA, Scharp CR, et al. Serum 25-hydroxy calciferol levels and bone mass in children on chronic antiepileptic therapy. N Engl J Med 1975;292:550-554
87. Kruse S, Suss A, Busse M, et al. Monometric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr 1987;111:57-63
88. Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteoblastic secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990;11:309-311
89. Pento JT, Hurt GM, Rajah T. Evaluation of calcium-mediated calcitonin secretion from the isolated pefused porcine thyroid using secretory inhibitors. Horm Metab Res 1996;27:107-109
90. Onodera K, Takahashi A, Sakurada S, et al. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002;70:1533-1542
91. Gracious B, Bossert RP, Puzas JE. Valproic acid inhibits osteoblast and osteoclast activity in therapeutic dose ranges. J Bone Miner Res 2004;M405(Suppl):abstract
92. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005;20:2254-2263
93. Kumandas S, Koklu E, Gümüs H, et al. Effect of carbamazepine and valproic acid on bone mineral density, IGF-1 and IGFBP-3. J Pediatr Endocrinol Metab 2006;19(4):529-534
94. Isojärvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008;17:111-119
95. Taubøll E, Røste LS, Svalheim S, et al. Disorders of reproduction in epilepsy - what can we learn from animal studies? Seizure 2008;17(2):120-126
96. Rattya J, Pakarinen AJ, Knip M, et al. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001;57(3):440-444
97. Taubøll E, Gregoraszczuk EL, Kolodzeij A, et al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003;44(8):1014-1021
98. Røste LS, Taubøll E, Isojärvi JIT, et al. Effects of chronic valproate treatment on reproductive endocrine hormones in female and male Wistar rats. Reprod Toxicol 2002;16:767-773
99. Taubøll E, Gregorasczuk EL, Wojtowicz AK, et al. Effects of levetiracetam and valproate on reproductive endocrine function studied in human ovarian follicular cells. Epilepsia 2009;50(8):1868-1874
100. Apeland T, Mansoor M, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocystein levels. Epilepsy Res 2001;47:27-35
101. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fractures in older persons. N Engl J Med 2004;350:2042-2051
102. Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007;16:22-34
103. Schroeder TM, Nair AK, Staggs R, et al. Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics 2007;8:362
104. Hamed SA, Abdella MM. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res 2009;86(1):32-41
105. Anil M, Helvaci M, Ozbal E, et al. Serum and muscle carnitine levels in epileptic children receiving sodium valproate. J Child Neurol 2009;24(1):80-86
106. Hooshmand S, Balakrishnan A, Clark RM, et al. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats. Phytomedicine 2008;15(8):595-601
107. Volpe SI, Schall JI, Gallagher PR, et al. Nutrient intake of children with intractable epilepsy compared with healthy children. J Am Diet Assoc 2007;107(6):1014-1018
108. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266-281
109. Bjørholt PG, Nakken KO, Røhme K, et al. Leisure time habits and physical fitness in adults with epilepsy. Epilepsia 1990;31(1):83-87
110. Dubow JS, Kelly JP. Epilepsy in sports and recreation. Sports Med 2003;33(7):499-516
111. Nakken KO. Physical exercise in outpatients with epilepsy. Epilepsia 1999;40(5):643-651
112. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289(5484):1501-1504
113. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006;4:341-348
114. Bhatt R, Bhatt S, Hameed M, et al. Amygdaloid kindled seizures can induce functional and pathological changes in thymus of rat: role of sympathetic nervous system. Neurobiol Dis 2006;21(1):127-137
115. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006;47(9):1447-1451
116. Elliott JO, Lu B, Moore JL, et al. Exercise, diet, health behaviors, and risk factors among persons with epilepsy based on California Health Interview Survey, 2005. Epilepsy Behav 2008;13(2):307-315